Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial
Auteurs / Authors: M. Wislez, J. Mazieres, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, V. Westeel, M. Antoine, D. Damotte
Journal / Conference: ESMO
Année / Year: 2021
PMID: Oral abstract
Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/pathological-response-is-an-independent-factor-of-overall-survival-and-disease-free-survival-after-neoadjuvant-durvalumab-in-resectable-non-small-c
